Anúncio
Anúncio
SYRE
Spyre Therapeutics, Inc. Common Stock
30.62
USDPatrocinado
+0.48
+1.59%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
30.98
+0.37
+1.20%
Relatórios de Lucros SYRE
Rácio de surpresa positiva
SYRE separação 17 de 39 últimas estimativas.
44%
Próximo Relatório
Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.78
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/+420.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/-3.70%
Spyre Therapeutics, Inc. Common Stock earnings per share and revenue
On 04 de nov. de 2025, SYRE reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.76 USD, resulting in a 80.30% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.57% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of -0.78 USD, with revenue projected to reach -- USD, implying an aumentar of 420.00% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Spyre Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Spyre Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 80.3%, and revenue of $0.00, 0% as expectations.
How did the market react to Spyre Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -0.57%, changed from $22.98 before the earnings release to $22.85 the day after.
When is Spyre Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Spyre Therapeutics, Inc. Common Stock's next earnings report?
Based on 15
analistas, Spyre Therapeutics, Inc. Common Stock is expected to report EPS of -$0.78 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio